Greg Roumeliotis

China’s HNA in talks to sell Ingram Micro to Apollo Global in $7.5b deal

HNA has already pushed ahead with asset sales that have so far included real estate and stakes in hotels groups.

Enterprise chat service firm Slack hires Goldman Sachs to lead IPO in 2019

The San Francisco-based company is among a string of Silicon Valley unicorns expected to debut in the stock market in 2019.

Logitech ends negotiations to acquire headphone maker Plantronics

Logitech and Plantronics were hoping to successfully conclude negotiations this week, but Logitech’s board decided on Sunday to walk away from the potential deal.

IBM to acquire software company Red Hat for $34b

The transaction is by far IBM’s biggest acquisition as the firm seeks to diversify its technology hardware and consulting business into higher-margin products and services.

Nielsen Holdings expands review to sell entire TV ratings firm

Nielsen is heavily indebted, the legacy of a leveraged buyout in 2006 by six private equity firms.

Musk’s Tesla buyout plan – No formal offer, no firm deals with advisers

Three members of Tesla’s board will now weigh whether it is advisable – or even feasible – to pursue what could be the biggest-ever go-private deal, and they are doing so before receiving a formal proposal from the CEO.

US retailer Party City rebuffs acquisition offer from China’s Meisheng Cultural

Meisheng Cultural’s unsuccessful acquisition attempt illustrates how some Chinese companies see opportunities in marrying their low-cost manufacturing base with U.S. retailers

Chipmaker Broadcom inks $19b deal to buy software firm CA

The CA deal comes just months after U.S. President Donald Trump blocked Broadcom’s $117 billion hostile bid for Qualcomm Inc.

T-Mobile agrees to acquire SoftBank-backed Sprint for $26b

The breakthrough in the companies’ negotiations came after T-Mobile majority-owner Deutsche Telekom and SoftBank agreed on a structure that will allow Deutsche Telekom to continue to consolidate the combined company, which will have a market value of over $80 billion, on its books.

Drug maker Shire rejects $63b Takeda bid as Allergan drops pursuit

Shire said Takeda’s proposals significantly undervalued the company’s growth prospects and drugs in development.